Skip to main content

Table 3 Association between myasthenia gravis and sick leave during 1 and 2-years follow up

From: Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997–2011: a Danish nationwide cohort study

 

≥9 weeks,

n (%)

Unadjusted OR

(95% CI)

Adjusted OR

(95% CI)a

Comparison groups

≥9 weeks sick leave, 1 year after diagnosis/match

MG vs. matched references

136 (41.2)/225 (3.4)

19.86 (15.37–25.67)

14.80 (10.97–19.95)

MG: age 40+ vs. 18–39

84 (42.9)/52 (38.8)

1.18 (0.76–1.85)

1.25 (0.70–2.24)

MG: male vs. female

50 (38.5)/86 (43.0)

0.83 (0.53–1.30)

0.66 (0.38–1.15)

MG: AChEI+ vs. AChEI

76 (44.2)/60 (38.0)

1.29 (0.83–2.01)

1.17 (0.70–1.96)

Comparison groups

≥9 weeks sick leave, 2 years after diagnosis/match

MG vs. matched references

155 (47.0)/448 (6.8)

12.16 (9.60–15.41)

8.60 (6.60–11.23)

MG: age 40+ vs. 18–39

94 (48.0)/61 (45.5)

1.10 (0.71–1.71)

1.34 (0.76–2.36)

MG: male vs. female

53 (40.8)/102 (51.0)

0.66 (0.42–1.0)

0.50 (0.29–0.86)

MG: AChEI+ vs. AChEI

91 (52.9)/64 (40.5)

1.65 (1.07–2.55)

1.61 (0.98–2.64)

  1. Abbreviations: MG myasthenia gravis, AChEI Acetylcholinesterase inhibitors, AChEI+ AChEI + immunosuppression, OR odds ratio, CI confidence interval
  2. aAdjusted for age, gender, profession, marital status, pharmacological treatment, sick leave 1 year before diagnosis/match, and time period